Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Potenza Therapeutics

- PMLiVE

Research units to close as Astellas restructures

US subsidiaries OSI Pharmaceuticals and Perseid Therapeutics among those affected

Pharma deals during April 2013

Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month

Deal Watch table for April 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

- PMLiVE

FDA committee turns down Aveo/Astellas’ cancer drug

Tivozanib unable to prove superiority to Bayer's Nexavar

- PMLiVE

Two new cancer drugs recommended in Europe

CHMP backing for Roche's Erivedge and Astellas' Xtandi

- PMLiVE

Hikma to retain injectables unit

Result of strategic review after acquisition interest

Astellas appoints Dr Songlin Xue head of global pharmacovigilance

He joins from Takeda and was formerly at Novartis and Wyeth

- PMLiVE

Merz pulls out of race for Obagi Medical

Leaves Valeant open to complete takeover

- PMLiVE

Pharma companies partner with Japanese government

GHIT Fund will support development of medicines for infectious diseases in developing countries

Pharma deals during March 2013

Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month

Astellas files diabetes drug ipragliflozin in Japan

Its SGLT2 inhibitor could beat AZ-BMS' rival Forxiga to debut in that market

Product updates from Japan

New approvals and filings include drugs from Takeda, Otsuka, Chugai and Astellas

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links